This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Final look: Understanding the impact, use, and prescribing patterns for XELJANZ (tofacitinib) in Rheumatoid Arthritis.

Ticker(s): PFE

Who's the expert?

Institution: Providence Medical Group

  • Board Certified Rheumatologist at Providence Medical Group (California); fellowship trained at University of California, San Francisco (UCSF)
  • Treats 15 patients with ANCA Associated Vasculitis with a focus on Ankylosing Spondylitis, Arthritis, Lupus, Rheumatoid Arthritis, Osteoporosis, Autoimmune Disorders, and Gout.
  • PI for several Rheumatology clinical trials, Medical Co-Director for Fracture Liaison Program, and Physician Site Director (Rheumatology).

Interview Goal
To understand the treatment layout for XELJANZ (tofacitinib) in Rheumatoid Arthritis.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.